Regulatory | Nanologica

Nanologica tar order på reningsmedia till ett värde om cirka 3,6 MSEK

29 November, 2023

Nanologica breddar sin produktportfölj av reningsmedia för preparativ kromatografi och har erhållit en provorder värd cirka 3,6 MSEK från en kund i Asien. Produktutveckling av detta reningsmedia, NLAB Siv™, har skett tillsammans med en kund som har ett flertal lanserade läkemedelsprodukter. NLAB Siv™ är ett icke-silikabaserat reningsmedia för preparativ kromatografi och tillverkning sker hos en tillverkningspartner. Utveckling har pågått med kunden under flera år och utvärdering av mindre mängder har gjorts under denna period. Kunden

Nanologica Receives Order of Purification Media Worth Approx. MSEK 3.6

29 November, 2023

Nanologica expands its product portfolio of purification medias for preparative chromatography and has received a trial order worth approximately MSEK 3.6 from a customer in Asia. Product development of this purification media, NLAB Siv™, has been conducted together with a customer who has a number of launched pharmaceutical products. NLAB Siv™ is a non-silica-based purification media for preparative chromatography and manufacturing takes place at a manufacturing partner. Development has been ongoing with the customer for

Delårsrapport Q3 2023 Nanologica AB (publ)

27 October, 2023

FINANSIELL SAMMANFATTNING • Nettoomsättningen för tredje kvartalet uppgick till 342 TSEK (401) och för niomånadersperioden till 1 368 TSEK (881) • Rörelseresultatet för kvartalet uppgick till -10 292 TSEK (-9 610) och för niomånadersperioden till -34 324 TSEK (-37 599) • Resultatet efter skatt för kvartalet uppgick till -11 554 TSEK (-10 988) och för niomånadersperioden till -38 318 TSEK (-40 376) • Resultat per aktie före och efter utspädning var -0,32 SEK (-0,39) för

Interim Report Q3 2023 Nanologica AB (publ)

27 October, 2023

FINANCIAL SUMMARY • Net sales for the third quarter amounted to TSEK 342 (401) and for the nine-month period to TSEK 1,368 (881) • The operating loss for the quarter amounted to TSEK -10,292 (-9,610) and for the nine-month period to TSEK -34,324 (-37,599) • Loss after tax for the quarter amounted to TSEK -11,554 (-10,988) and for the nine-month period to TSEK -38,318 (-40,376) • Earnings per share before and after dilution were SEK

Nanologicas valberedning utsedd inför årsstämman 2024

26 October, 2023

I enlighet med beslut på årsstämman den 4 maj 2023 har styrelsens ordförande kontaktat Nanologicas tre röstmässigt största ägare eller ägargrupper per den 30 september 2023, som var och en har utsett en representant att utgöra valberedning i Nanologica AB inför årsstämman 2024. Valberedningen inför Nanologica AB:s årsstämma 2024 utgörs därmed av följande tre ledamöter: Carl-Johan Spak (Flerie Invest AB) Lennart Francke (Swedbank Robur Microcap) Kalle Olby (Vega Bianca AB) Valberedningen representerar tillsammans 53,3 procent

Nanologica Announces Nomination Committee for the Annual General Meeting 2024

26 October, 2023

In accordance with the resolution at the Annual General Meeting (“AGM”) on May 4, 2023, the chairman of the board has contacted Nanologica’s three largest owners or ownership groups in terms of votes as of September 30, 2023, each of whom has appointed a representative to constitute the nomination committee of Nanologica AB for the 2024 AGM. The nomination committee for Nanologica AB's 2024 AGM thus consists of the following three members: Carl-Johan Spak (Flerie

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.